CAT No

CAS No

MW

MF

CAT No

CAS No

MW

MF

:

:

:

:

:

:

:

:

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

Alfuzosin

For more information on our products custom synthesis, contact SynZeal today.

standards@synzeal.com www.synzeal.com

SZ-A010001

Alfuzosin HCl

81403-68-1

C19H28ClN5O4

425.91

SZ-A010002

Alfuzosin EP Impurity A

98902-29-5

C19H24CIN5O4

421.9

SZ-A010003

Alfuzosin EP Impurity B

23680-84-4

C10H10CIN3O2

239.7

SZ-A010004

Alfuzosin EP Impurity C

72104-34-8

C19H18CIN5O4

425.9

SZ-A010005

Alfuzosin EP Impurity D

81403-69-2

C14H22CIN5O2

327.8

SZ-A010006

Alfuzosin EP Impurity E

1026411-59-5

C15H22CIN5O3

355.8

SZ-A010007

Alfuzosin EP Impurity F

19216-53-6

C12H16N4O2

248.29

SZ-A010008

Alfuzosin Impurity 2

NA

C20H29N5O4

403.49

SZ-A010009

Alfuzosin EP Impurity G

928780-95-4

C24H30N8O4

494.56

SZ-A010010

Alfuzosin Impurity 3

1250263-67-2

C28H39N9O4

565.68

Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. Alfuzosin was approved by the U.S. FDA for treatment of BPH in June 2003. It is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradenames Xat, Xatral, Prostetrol and Alfural.

SynZeal Research offers all related impurities which certified COA with all characterization data like IR, Mass, HPLC Alfuzosin purity,NMR & TGA report. We also provide CMR, DEPT and detailed structurecharacterization report as perrequirements.

related products are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.Alfuzosin